Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.

X
Trial Profile

A First-in-human, Open-label, Multiple Center Phase 1 Dose-Escalation Study to Evaluate Safety, Tolerability, Pharmacokinetic, Immunogenicity, and Preliminary Efficacy of F182112 in Patients With Relapsed or Refractory Multiple Myeloma.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs F 182112 (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions; First in man
  • Sponsors Shandong New Time Pharmaceutical Co LTD
  • Most Recent Events

    • 12 Dec 2023 Results (n=22) assessing the safety and efficacy of F182112 in patients with relapsed/refractory multiple myeloma, presented at the 65th American Society of Hematology Annual Meeting and Exposition.
    • 06 Jun 2023 Results (n=16; As of Feb 2,2023) assessing the efficacy and safety of F182112 in patients with relapsed/refractory multiple myeloma, presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 04 Aug 2021 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top